Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 13/20 | 0.63 |
| ▸ | PPARA | Q07869 | 4/20 | 0.58 |
| ▸ | PPARG | P37231 | 4/20 | 0.58 |
| ▸ | AKT1 | P31749 | 1/20 | 0.57 |
| ▸ | PTGES | O14684 | 1/20 | 0.54 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16136834 | 0.92 | ALOX5 (0.63) | ALOX5PPARAPPARGPTGESNR1I2 | |
| SCHEMBL9321468 | 0.89 | ALOX5 (0.64) | ALOX5PPARAPPARGPTGESNR1I2 | |
| SCHEMBL16589599 | 0.87 | ALOX5 (0.68) | ALOX5PPARAPPARGPTGESNR1I2 | |
| SCHEMBL17681925 | 0.87 | ALOX5 (0.68) | ALOX5PPARAPPARGPTGESNR1I2 | |
| SCHEMBL29592892 | 0.87 | ALOX5 (0.58) | ALOX5PPARAPPARGPTGESNR1I2 | |
| SCHEMBL27140499 | 0.87 | ALOX5 (0.58) | ALOX5PPARAPPARGPTGESNR1I2 | |
| SCHEMBL27091706 | 0.87 | ALOX5 (0.58) | ALOX5PPARAPPARGPTGESNR1I2 | |
| SCHEMBL27091599 | 0.87 | ALOX5 (0.58) | ALOX5PPARAPPARGPTGESNR1I2 | |
| SCHEMBL29591891 | 0.87 | ALOX5 (0.58) | ALOX5PPARAPPARGPTGESNR1I2 | |
| SCHEMBL29592406 | 0.87 | ALOX5 (0.58) | ALOX5PPARAPPARGPTGESNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133225-B2 | Dual targeting anticancer agents | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-09-15 | — | — | US | disclosed |
| US-20140274988-A1 | DUAL TARGETING ANTICANCER AGENTS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140274988-A1 | DUAL TARGETING ANTICANCER AGENTS | CCNE1, CCNE2, VHL | ALOX5 2194/4885PPARA 238/4885PPARG 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.